PRZOOM - /newswire/ -
Winston-Salem, NC, United States, 2014/01/09 - SmallCapReview.com, A leading site for news and information on small caps, penny stocks and microcaps is adding Intercept Pharmaceuticals (ICPT) to its list of stocks "On the Radar".
Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry.
The company's lead product candidate, obeticholic acid, is a bile acid analog and first-in-class agonist of the farnesoid X receptor. OCA is being developed for a variety of chronic liver diseases including NASH, primary biliary cirrhosis, portal hypertension and bile acid diarrhea. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC.
Intercept owns worldwide rights to OCA outside of Japan and China.
ICPT Investor Highlights
Announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met.
"The unexpected early stopping of FLINT due to OCA meeting the primary endpoint with such high significance is a major milestone," said Mark Pruzanski, M.D., Chief Executive Officer of Intercept. "NASH has grown to epidemic proportions worldwide, having become a leading cause of cirrhosis and liver failure."
As of September 30, 2013, Intercept's cash, cash equivalents and investment securities available for sale totaled approximately $156.8 million, compared to $110.2 million at December 31, 2012.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated for its services with regards to Intercept Pharmaceuticals.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.